From: Cook, David [mailto:email@example.com]
Sent: Thursday, February 25, 2016 10:48 AM
To: Barnes, Desiree N. EOP/WHO
Subject: Pool Report #1 -- Background for Precision Medicine Initiative Summit
The White House Precision Medicine Initiative Summit, being held in the South Court Auditorium, is open press and being live streamed on the White House website.
Here is background from the White House on participants in the panel discussion with the President. That panel has not yet begun.
The Christian Science Monitor
Dr. James Hamblin, The Atlantic
Ph.D. student, Broad Institute of MIT and Harvard
Vallabh was a recent law school graduate working in consulting when she learned, in late 2011, that she carries the genetic mutation that caused her mother to abruptly develop and die of prion disease the year before. Along with her husband, Eric Minikel, Vallabh changed careers to train in the biomedical sciences. She worked for two years with induced pluripotent stem cell models of Huntington's disease at Massachusetts General Hospital before joining the Biological and Biomedical Sciences Ph.D. program at Harvard Medical School. Sonia currently works at the Broad Institute, where she and Eric are focused on developing therapies for prion disease.
President, CEO, and Founder, Tidepool
Howard Look is President, CEO, and Founder of Tidepool, a non-profit organization with the mission of reducing the burden of managing Type 1 Diabetes through their open source software. Tidepool works closely with diabetes device makers to liberate patient-owned health data and make it available through the secure Tidepool Platform. Previously, Howard was on the founder’s team at TiVo where as VP of Software and User Experience he led the efforts that made TiVo as easy to use as it was disruptive. He was also VP of Software at Pixar, where he led the team developing Pixar’s proprietary film-making system, and at Amazon where he ran a secret software project to develop devices that leverage cloud services.
W. Marston Linehan, M.D.
Chief, Urologic Oncology Branch, National Cancer Institute
Dr. Linehan and his colleagues pioneered the study of the genetic basis of kidney cancer. His team identified the genes for the common forms of kidney cancer and described the pathways of these kidney cancer genes. His group’s recent studies targeting the metabolic basis of kidney cancer have resulted in the regression of metastatic cancer in patients with type 1 and type 2 papillary kidney cancer. Dr. Linehan oversees the Branch’s clinical/translational research program, which emphasizes new approaches to the therapies of genitourinary cancers, diagnostic and prognostic evaluation of solid GU tumors, and the development of innovative surgical and targeted therapeutic approaches for the treatment of patients with localized as well as advanced urologic cancer.